Monitor for rare events like pancreatitis & gallbladder disease
Your Starting Weight and Metabolism People with a higher starting weight often see faster initial weight loss, while those with a lower BMI may experience more gradual progress
[1] GLP-1s remain covered for: BMI 40 (Class III/morbid obesity) Type 2 Diabetes (Mounjaro, not Zepbound) Major Adverse Cardiac Events history Employers who opt-in to add weight loss drug coverage California Medi-Cal Alert: GLP-1 Exclusion Effective January 1, 2026 If you have Kaiser through Medi-Cal, weight loss GLP-1 coverage is ending
This side effect can often be managed with simple lifestyle changes, including increased water and fiber intake
As people continue to seek effective ways to manage their weight, evaluating the benefits and drawbacks of such options is essential
Drug Classification Overview Rybelsus is an oral glucagon-like peptide-1 (GLP-1) receptor agonist